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Following cues frommouse embryogenesis, Chal et al. (2015) identified key regulators of skeletalmyogenesis
frommouse and human pluripotent stem cells. Emergingmyogenic progenitors were specified to formmulti-
nucleated fibers that enabled development of quiescent, satellite cell-like progenitors and a model for
Duchenne Muscular Dystrophy.Recapitulating the complexity of skeletal
myogenesis in vitro from pluripotent
stem cells (PSCs) has presented
numerous challenges for the field. The
longstanding protocols for generating
skeletal muscle require viral-mediated
overexpression of transcription factors
such as Myogenic Differentiation 1
(MYOD) or Paired Box 7 (PAX7) that limit
the generation of truly representative
myogenic progenitors and the ability to
accurately model muscle diseases in a
dish. Skeletal myogenesis relies on tightly
controlled spatial and temporal cues
to ensure timely embryonic transition
through the presomitic mesoderm, the
somites, and dermomyotome to form the
myotome. Skeletal muscle progenitors
delaminate from the dermomyotome to
seed individual muscles and eventually
give rise to satellite cells, the endogenous
stem cells in skeletal muscle responsible
for adult homeostasis and repair. Har-
nessing the genetic instructions of this
developmental process enabled Chal
et al. to differentiate PSCs to skeletalmus-
cle in vitro (Chal et al., 2015) (Figure 1).
To better understand the in vivo land-
scape they were aiming to recapitulate,
Olivier Pourquie´ and colleagues devel-
oped a detailed expression profile of
mouse presomitic mesoderm (PSM)
(Chal et al., 2015). The PSM is dynamic.
Somites are generated at the anterior
end, while the posterior end is continually
renewed with new cells entering from the
tail bud. The formation of somites from
the PSM gives rise to the axial skeleton
and skeletal muscles. An evaluation of in-
ducers of posterior PSM specification
in vivo identified a 300-fold increase in
expression of the secreted factor R-spon-din3 (Rspo3), a Wingless-Type MMTV
Integration Site Family (WNT) signaling
molecule. Similar studies have also
shown that WNT is a key inducer of early
skeletal myogenic fate in both model or-
ganisms as well as PSCs (Borchin et al.,
2013; Mendjan et al., 2014; Shelton
et al., 2014; von Maltzahn et al., 2012;
Xu et al., 2013). The prior central dogma
of mesoderm specification from PSCs
normally involved activation of Bone
Morphogenetic Protein (BMP) signaling
(Kattman et al., 2011; Mendjan et al.,
2014), which traditionally activates the
lateral plate mesoderm and cardiomyo-
cyte differentiation. Chal et al. found that
inhibition, not activation, of BMP is critical
to coaxing the majority of mouse embry-
onic stem cells (mESCs) to adopt a
PSM fate. Importantly, at each step,
Chal et al. profiled mESC-derived Meso-
genin 1 (Msgn1; posterior) and Paired
Box 3 (Pax3; anterior) cells and compared
them to endogenous mouse posterior
and anterior PSM cells in vivo. By
following developmental myogenic cues,
they were able to develop a scalable pro-
tocol that recapitulates differentiation
stages of PSM to generate Pax3-positive
myogenic precursor cells, an important
first step toward differentiating skeletal
muscle in vitro from PSCs.
Skeletal muscle is generated in waves
during embryogenesis when Pax3-posi-
tive cells undergoing primary (embryonic)
myogenesis give rise to Pax7-positive
myogenic precursors during secondary
(fetal) myogenesis that fuse to form multi-
nucleated muscle fibers (Buckingham
et al., 2003). After identification of in vitro
differentiation conditions to derive Pax3-
positive cells, Chal et al. induced theseCell Stem Cell 17, Scells toward secondary myogenesis by
applying known developmental growth
factors including hepatocyte growth fac-
tor (Hgf), insulin growth factor 1 (Igf-1),
and fibroblast growth factor 2 (Fgf-2).
Additional mechanistic studies will be
required to determine the role of each
factor during skeletal myogenesis from
PSCs. Pax7 and Myogenin (Myog) re-
porters were both utilized to monitor effi-
ciencies of differentiating muscle fibers
and after just 2–3 weeks in culture, the
Pax7-positive cells gave rise to several
thousand multinucleated muscle fibers
that express fast Myosin Heavy Chain
(MyHC), a mature muscle marker.
These myofibers contained a remarkable
amount of myonuclei (approximately
25–50), which had not previously been
feasibly generated from PSCs.
Pax7-positive satellite cells are the ma-
jor source of regenerative cells in skeletal
muscle and could be used as a cell-based
therapy to repair or replace damaged
myofibers. A holy grail for Duchenne
Muscular Dystrophy (DMD) cell-based
therapies is toobtain satellite cells capable
of genetic modification ex vivo and con-
tinuous expansion while able to retain
their stemness. The discovery that donor
myoblasts could restore dystrophin ex-
pression in dystrophin-deficient mice set
the precedent for a number of clinical trials
in the 1990s to restore muscle function
in DMD patients (Tremblay et al., 1993).
Unfortunately, myoblasts cannot continu-
ously repopulate the satellite cell pool,
which led to their failure. Chal et al. provide
tantalizing evidence that the developmen-
tally guided protocol derives Pax7-posi-
tive cells residing inside the myofiber
basal lamina that are Ki67 negative andeptember 3, 2015 ª2015 Elsevier Inc. 255
Figure 1. Developmental Myogenesis Guides In Vitro Differentiation
(A) Timeline of skeletal myogenesis from E9.5–E16 mouse embryo. Left to right: images depict a mid-sagittal cross section of a mouse embryo during develop-
ment and longitudinal sections of three somites. The somites give rise to the dermomyotome/myotome andmigratory muscle progenitor cells that seed the limbs
and mature to multinucleated fibers. Arrows indicate specific regions in the developing embryo (black).
(B) Micro dissections of tissue regions between the first somite (S1) and tail bud were collected and profiled to aid in the identification of novel targets to drive
in vitro myogenesis of mouse embryonic stem cells (mESCs). Not determined refers to the lack of profiling of the myotome and muscle fibers in this work.
(C) The corresponding in vitro cells differentiated from mESCs using developmentally identified growth factors and small molecules are shown. Green nuclei
indicate that Chal et al. utilized a reporter to monitor differentiation efficiency at each stage. pPSM, posterior presomitic mesoderm; aPSM, anterior presomitic
mesoderm; S1, newly formed somite; DM, dermomyotome; M, myotome; LB, limb bud.
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Previewspotentially quiescent. When engrafted in
vivo, the Pax7-positive cells were able to
home to the satellite cell position and
fuse with myofibers to restore expression
of muscle proteins including dystrophin.
Chal et al. adapted their developmen-
tally derived mESC protocol to human
pluripotent stem cells (hPSCs) that
included modifications to timing and con-
centrations of supplemented factors. The
optimized hPSC differentiation method
derived PAX7-positive cells in 3 weeks
and resulted in 50,000–70,000 fast
MyHC fibers starting from 75,000 cells in
30 days. The muscle fibers showed orga-
nized sarcomeres and exhibited sponta-
neous twitching. However, in contrast to
the mESC-derived myofibers, the human
myofibers were 3- to 4-fold smaller in
diameter and had reduced multinuclea-
tion. Devising methods to further mature
human fibers in vitro, as well as engrafting
the human PAX7-positive cells in vivo to
demonstrate their functional potential,
are important next steps in understanding
the true myogenic potential of the hPSC-256 Cell Stem Cell 17, September 3, 2015 ª2derived skeletal myogenic progenitor
cells. Overall the developmentally derived
protocol presents a significant step for-
ward in the field by improving the effi-
ciency and timing for the generation of
human-derived MyHC-positive fibers.
There is a significant need in the field
to develop protocols for obtaining physio-
logically relevant skeletal muscle cells
in order to effectively model muscle dis-
eases. By applying their skeletal muscle
differentiation protocol to mESCs derived
from mdx mice, a mouse model of DMD
lacking dystrophin, Chal et al. were able
to model aspects of DMD that have
not previously been seen in vitro. They
found that in vitro myotubes lacking
dystrophin had increased lateral branch-
ing, consistent with myofiber splitting
observed in some neuromuscular dis-
eases. Previous work in the field (Pavlath,
2010) suggests that defective myoblast
fusion may contribute to aberrant branch-
ing and thus dystrophin may play a role
in regulating membrane fusion between
adjacentmyoblasts.Aclearer understand-015 Elsevier Inc.ing for the role of dystrophin in muscle
development and its effects on themuscle
membrane stability remains to be clarified.
In muscle wasting diseases such as
DMD, the endogenous satellite cells
become exhausted over time and get
replaced by fat and fibrotic tissue. The
ability to generate an efficient protocol
for producing skeletal muscle from PSCs
provides a unique in vitro model for
improving our understanding of the con-
sequences of dystrophin loss in human
skeletal muscle. Optimization and further
characterization of the muscle progenitor
cells derived from hPSCs could provide
a remarkable source of cells with repopu-
lation potential to replace exhausted sat-
ellite cells in DMD.REFERENCES
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